
ABOUT CITELINE
Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth.
Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.
FEATURED CONTENT
-
The best way to address clinical trial recruitment challenges is with a multifaceted approach that goes beyond traditional channels and ways of thinking.
-
Discover how Citeline’s robust datasets, combined with real-world data, inform intelligent site and investigator selection for a rare, autoimmune disease.
-
Explore the results of a survey where senior decision-makers in the life sciences industry provided their perceptions and expectations of AI to understand current AI adoption trends.
-
Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.
-
Explore the updated guidance from the FDA to enhance diversity in clinical trials, including ten times to developing a comprehensive Diversity Action Plans.
-
To make the best use of artificial intelligence (AI), drug sponsors need to understand where health authorities are drawing the lines.
-
In 2025, the FDA will require pharmaceutical companies to include diversity action plans (DAPs) for Phase II and pivotal studies.
-
The clock is ticking on the requirement for pharmaceutical companies to include FDA-mandated diversity action plans for pivotal studies in clinical trials.
-
Learn about the eight key domains that are assessed by the clinical trial disclosure maturity model.
-
Unlock the full potential of AI to address sponsor challenges including regulatory complexity, clinical trial disclosure requirements, and growing demands for transparency.
-
How could leveraging AI technologies, including machine learning (ML) and generative AI (GenAI), enable your company to streamline processes from drug discovery to post-launch?
-
This report explores how clinical trials bounced back in 2023 from their decline a year earlier despite continued geopolitical, regulatory, and pricing pressures.
-
A comprehensive maturity model for clinical trial disclosure and transparency offers companies a strategic tool to assess and enhance their practices in an increasingly complex regulatory environment.
-
In this text we explore strategic solutions to patient recruitment and engagement challenges, emphasizing the importance of comprehensive patient engagement and recruitment strategies.
-
Synthetic data is a form of generative artificial intelligence (AI) that, in the life sciences, is especially valuable for enhancing datasets and increasing diversity in clinical trials.
-
Claire Riches, Citeline's VP of Clinical Solutions, emphasizes that clinical trial diversity must start with a fit-for-purpose protocol, incorporating the patient voice early on to ensure success in reaching diverse populations.
-
Although the FDA mandate on diversity action plans won’t come until 2025, sponsors should start planning how to be inclusive, increasing the representation of underrepresented groups in clinical trials and reporting that data.
-
In an ACRP webinar on LGBTQIA+ diversity in clinical trials, industry panelists came together to discuss FDA action plans, SOGI data, advocacy efforts, challenges of transgender patients, and more.
-
Gain insights on FDA diversity action plans, and the important role that data points play in ensuring inclusion of underrepresented populations.
-
A total of 24 drugs, devices, diagnostics, and deals are expected to progress in the third quarter of 2024, including approval applications for 17 drugs. The estimated overall likelihood of approval is 90% or higher for seven of those drugs, including revumenib for acute myelogenous leukemia and KarXT for schizophrenia.
CONTACT INFORMATION
Citeline
605 Third Ave.
New York, NY 10158
UNITED STATES
Phone: 1 212-600-3530
Contact: Steven Horlock
FEATURED SOLUTIONS
- How Can You Simplify Disclosure Compliance For Global Clinical Trials?
- Drive Patient Enrollments With Data-Powered Recruitment Engine
- RWD & Human Insight From Consulting & Analytics
- Meeting Our Customers Real-World Data Needs
- Creating A New World In Clinical Trial Feasibility Utilizing Advanced Analytics
- Feasibility As A Service From Consulting & Analytics
- Informed Diversity Action Planning Made Simple
- Citeline SmartSolutions
- Investigator SmartSelect
- Data-Backed Recommendations For Primary Endpoints And I/E Criteria
- Leverage AI To Optimize Protocol Design & Study Start-Up
- What is Citeline Connect?
- Optimize Protocols For More Successful Trials
- Citeline Patient Engagement & Recruitment Solutions
- Streamline The Clinical Trial Disclosure Process
FEATURED WEBINARS
-
A growing number of countries are requiring clinical trial protocol and results disclosures to be written in plain language, influencing how these documents are authored.
-
Gain comprehensive insights into diversity action plans in clinical trials through this informative presentation, focusing on the latest FDA guidelines for collecting race and ethnicity data.
-
Compliance is more important than ever. Keep up with how regions are enforcing disclosure requirements by learning how to adjust compliance strategies accordingly.
-
Taken from a spotlight session at the CNS Summit, gain insights from thought leaders from Norstella and Citeline regarding artificial intelligence and real-world data.
-
Consider this diverse range of real-world perspectives, complemented by data-driven insights, when looking to enhance the speed, accessibility, and efficiency of clinical trial processes.
-
Listen in as industry leaders discuss how to meet the needs of multiple stakeholders while ensuring operational efficiency, study success, and enterprise scale.
-
See the results of a joint survey with 1nHealth on how compensation is likely to impact participation in clinical trials, followed by a thought-provoking roundtable on this timely topic.
-
In this webinar, discover the trends shaping pharma’s R&D pipeline, with data broken down by therapeutic area, disease, mechanism and target, and drug type.
-
Now that the EU’s Clinical Trials Information System (CTIS) is up and running, disclosure and transparency experts from Sarepta, Boehringer Ingelheim, Bayer and Merck KgaA discuss the ins and outs of registering clinical trials and submitting study information to the portal.
-
Disclosure experts Thomas Wicks and Francine Lane explain the importance of consistency and creating a disclosure template, plain language summaries source documents, and authoring with redaction in mind.